Synaptic dysfunction is a key feature of Alzheimer's disease (AD) and closely correlates with memory impairment. Activity-dependent production of Ap, and targeted accumulation of Ap oligomers at the synapse have been reported, however underlying molecular mechanisms remain poorly understood. We have previously suggested that presenilin (PSI) can adopt one of two conformations -termed """"""""open"""""""" and closed"""""""", based on the other protein constituents of the gamma-secretase complex (Serneels et al., 2009,), on the effects of GAMMA-secretase modulators (Uemura et al., 2010), or due to familial AD-related mutations in PSI (Berezovska et al., 2005). However, whether these are different gamma-complexes that are in equilibrium with one another within a cell, or PSI can dynamically change its conformation within a specific complex, is unclear. Furthermore, events and/or protein(s) that may be involved in regulation of PSI conformation and function in the cell remain unknown. Now we established a unique conformation-sensitive FRET-based assay in living cells, and our new preliminary data show that conformation of PSI changes rapidly and reversibly in concert with synaptic activity.
Aim1 will build on this observation and extend it to PSI-APP interactions at the synapse. To search for potential activity-dependent modulators of PSI conformation, we performed a proteomics screen of mouse brain lysates in the presence or absence of calcium, and identified several novel PSI interactors, including synaptotagminsi and 9 (Sytl .9), and synapsini (Svnl). Since Syt1 and Synl showed strong but opposing Ca-dependent profiles of interaction with PSI, we will direct our initial attention to these as likely candidates to modulate PSI/gamma-secretase and its interaction with APP at the synapse in an activity-gamma-controlled manner. Intriguingly, Sytl and 9 were also identified in an independent proteomics screen performed by Dr. Kovacs as APP-interacting proteins (Project 4).
Aim 2 will test the hypothesis that Ca2+ influx serves as a switch between the two PSI conformational states in the synaptosomal compartment by controlling PSI interactions with synaptic proteins.
Aim 3 follows on the idea that PSI can undergo rapid and reversible changes in conformation to examine the role of pharmacological interventions in allosteric modulation of PSI/gamma-secretase (collaboration with Projects 1 and 2), and its interactions with synaptic proteins in vitro and in vivo. Understanding this issue is of high importance both because the """"""""closed"""""""" PSI conformation is associated with increased Ap42 (the AD-associated cleavage) and because manipulation of the PS1 interactions with Sytl and Synl may be translated into therapeutics with a focus on the synapse.

Public Health Relevance

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders for which no cure is available. Due to the increased average population age, and thus increased number of affected individuals and associated tremendous healthcare costs, AD has become an urgent public health concern in the U.S. By deciphering the mechanisms underlying the pathogenesis and disease progression we will be able to develop new therapeutics to prevent or halt the disease

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG015379-16A1
Application #
8633651
Study Section
Special Emphasis Panel (ZAG1-ZIJ-6 (02))
Project Start
Project End
Budget Start
2013-09-30
Budget End
2014-06-30
Support Year
16
Fiscal Year
2013
Total Cost
$445,639
Indirect Cost
$19,114
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Zoltowska, Katarzyna Marta; Berezovska, Oksana (2017) Dynamic Nature of presenilin1/?-Secretase: Implication for Alzheimer's Disease Pathogenesis. Mol Neurobiol :
Gong, Yi; Sasidharan, Nikhil; Laheji, Fiza et al. (2017) Microglial dysfunction as a key pathological change in adrenomyeloneuropathy. Ann Neurol 82:813-827
Kara, Eleanna; Marks, Jordan D; Fan, Zhanyun et al. (2017) Isoform- and cell type-specific structure of apolipoprotein E lipoparticles as revealed by a novel Forster resonance energy transfer assay. J Biol Chem 292:14720-14729
Raven, Frank; Ward, Joseph F; Zoltowska, Katarzyna M et al. (2017) Soluble Gamma-secretase Modulators Attenuate Alzheimer's ?-amyloid Pathology and Induce Conformational Changes in Presenilin 1. EBioMedicine 24:93-101
Wagner, Steven L; Rynearson, Kevin D; Duddy, Steven K et al. (2017) Pharmacological and Toxicological Properties of the Potent Oral ?-Secretase Modulator BPN-15606. J Pharmacol Exp Ther 362:31-44
Yang, Ting; Li, Shaomin; Xu, Huixin et al. (2017) Large Soluble Oligomers of Amyloid ?-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. J Neurosci 37:152-163
Ward, Joseph; Wang, Haizhi; Saunders, Aleister J et al. (2017) Mechanisms that synergistically regulate ?-secretase processing of APP and A?-? protein levels: relevance to pathogenesis and treatment of Alzheimer's disease. Discov Med 23:121-128
Zoltowska, Katarzyna Marta; Maesako, Masato; Lushnikova, Iryna et al. (2017) Dynamic presenilin 1 and synaptotagmin 1 interaction modulates exocytosis and amyloid ? production. Mol Neurodegener 12:15
Bolduc, D M; Selkoe, D J; Wolfe, M S (2017) Enzymatic Assays for Studying Intramembrane Proteolysis. Methods Enzymol 584:295-308
Williamson, Rebecca L; Laulagnier, Karine; Miranda, André M et al. (2017) Disruption of amyloid precursor protein ubiquitination selectively increases amyloid ? (A?) 40 levels via presenilin 2-mediated cleavage. J Biol Chem 292:19873-19889

Showing the most recent 10 out of 139 publications